Cargando…

Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives

Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), spinal cord injury (SCI), and amyotrophic lateral sclerosis (ALS), are characterized by acute or chronic progressive loss of one or several neuronal subtypes....

Descripción completa

Detalles Bibliográficos
Autores principales: El Ouaamari, Yousra, Van den Bos, Jasper, Willekens, Barbara, Cools, Nathalie, Wens, Inez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968045/
https://www.ncbi.nlm.nih.gov/pubmed/36835277
http://dx.doi.org/10.3390/ijms24043866
_version_ 1784897416903786496
author El Ouaamari, Yousra
Van den Bos, Jasper
Willekens, Barbara
Cools, Nathalie
Wens, Inez
author_facet El Ouaamari, Yousra
Van den Bos, Jasper
Willekens, Barbara
Cools, Nathalie
Wens, Inez
author_sort El Ouaamari, Yousra
collection PubMed
description Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), spinal cord injury (SCI), and amyotrophic lateral sclerosis (ALS), are characterized by acute or chronic progressive loss of one or several neuronal subtypes. However, despite their increasing prevalence, little progress has been made in successfully treating these diseases. Research has recently focused on neurotrophic factors (NTFs) as potential regenerative therapy for neurodegenerative diseases. Here, we discuss the current state of knowledge, challenges, and future perspectives of NTFs with a direct regenerative effect in chronic inflammatory and degenerative disorders. Various systems for delivery of NTFs, such as stem and immune cells, viral vectors, and biomaterials, have been applied to deliver exogenous NTFs to the central nervous system, with promising results. The challenges that currently need to be overcome include the amount of NTFs delivered, the invasiveness of the delivery route, the blood–brain barrier permeability, and the occurrence of side effects. Nevertheless, it is important to continue research and develop standards for clinical applications. In addition to the use of single NTFs, the complexity of chronic inflammatory and degenerative diseases may require combination therapies targeting multiple pathways or other possibilities using smaller molecules, such as NTF mimetics, for effective treatment.
format Online
Article
Text
id pubmed-9968045
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99680452023-02-27 Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives El Ouaamari, Yousra Van den Bos, Jasper Willekens, Barbara Cools, Nathalie Wens, Inez Int J Mol Sci Review Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), spinal cord injury (SCI), and amyotrophic lateral sclerosis (ALS), are characterized by acute or chronic progressive loss of one or several neuronal subtypes. However, despite their increasing prevalence, little progress has been made in successfully treating these diseases. Research has recently focused on neurotrophic factors (NTFs) as potential regenerative therapy for neurodegenerative diseases. Here, we discuss the current state of knowledge, challenges, and future perspectives of NTFs with a direct regenerative effect in chronic inflammatory and degenerative disorders. Various systems for delivery of NTFs, such as stem and immune cells, viral vectors, and biomaterials, have been applied to deliver exogenous NTFs to the central nervous system, with promising results. The challenges that currently need to be overcome include the amount of NTFs delivered, the invasiveness of the delivery route, the blood–brain barrier permeability, and the occurrence of side effects. Nevertheless, it is important to continue research and develop standards for clinical applications. In addition to the use of single NTFs, the complexity of chronic inflammatory and degenerative diseases may require combination therapies targeting multiple pathways or other possibilities using smaller molecules, such as NTF mimetics, for effective treatment. MDPI 2023-02-15 /pmc/articles/PMC9968045/ /pubmed/36835277 http://dx.doi.org/10.3390/ijms24043866 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
El Ouaamari, Yousra
Van den Bos, Jasper
Willekens, Barbara
Cools, Nathalie
Wens, Inez
Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives
title Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives
title_full Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives
title_fullStr Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives
title_full_unstemmed Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives
title_short Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives
title_sort neurotrophic factors as regenerative therapy for neurodegenerative diseases: current status, challenges and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968045/
https://www.ncbi.nlm.nih.gov/pubmed/36835277
http://dx.doi.org/10.3390/ijms24043866
work_keys_str_mv AT elouaamariyousra neurotrophicfactorsasregenerativetherapyforneurodegenerativediseasescurrentstatuschallengesandfutureperspectives
AT vandenbosjasper neurotrophicfactorsasregenerativetherapyforneurodegenerativediseasescurrentstatuschallengesandfutureperspectives
AT willekensbarbara neurotrophicfactorsasregenerativetherapyforneurodegenerativediseasescurrentstatuschallengesandfutureperspectives
AT coolsnathalie neurotrophicfactorsasregenerativetherapyforneurodegenerativediseasescurrentstatuschallengesandfutureperspectives
AT wensinez neurotrophicfactorsasregenerativetherapyforneurodegenerativediseasescurrentstatuschallengesandfutureperspectives